The BioCentury Show
- Épisodes
- 76
- Parution
- toutes les deux semaines
- Dernier épisode
- 13 Nov 2026
À propos du podcast
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.
Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.
The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.
Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
Participants
Épisodes 76
Ep. 124 - Texas Medical Center’s William McKeon on making Texas the U.S. pilot for faster trials
Texas Medical Center CEO William McKeon wants Texas to serve as the U.S. pilot for faster, cheaper clinical trials. In an interview with BioCentury Editor in Chief Simone Fishburn on The BioCentury Show, McKeon …
Notes de l’épisode
Texas Medical Center CEO William McKeon wants Texas to serve as the U.S. pilot for faster, cheaper clinical trials. In an interview with BioCentury Editor in Chief Simone Fishburn on The BioCentury Show, McKeon described how TMC’s centralized IRB gives sponsors a single approval covering 10 million patients, and his push to extend it statewide. He also discussed competition from China, Australia and Spain for early-stage trials and a proposed Australia-style refundable R&D tax credit for the upcoming Texas legislative session. This episode of The BioCentury Show has been brought to you by Tigermed.
View full story: https://www.biocentury.com/article/661560
#ClinicalTrials #LifeSciences #HealthPolicy #Texas #ClinicalResearch
0:00 Introduction
01:15 TMC in a Nutshell
11:57 A Model for the U.S.
15:23 Competing with China
18:46 Policy Proposals: Tax Credit
27:47 Embedding Trials in CareChapitres (6)
Ep. 123 - Gilde’s Joep Muijrers on why patients belong in the investment process
On this edition of The BioCentury Show, Gilde's Joep Muijrers joins BioCentury’s Stephen Hansen to discuss how the firm’s Impact Council of former regulators, payers, HTA leaders, and patient advocates …
Notes de l’épisode
On this edition of The BioCentury Show, Gilde's Joep Muijrers joins BioCentury’s Stephen Hansen to discuss how the firm’s Impact Council of former regulators, payers, HTA leaders, and patient advocates shapes its investment decisions. Muijrers explains how council input steered Gilde away from one deal and toward another, diagnostics company Karius, and why he argues patient perspectives belong alongside physician input in diligence and development strategy. He also describes the frameworks Gilde has developed for engaging patient organizations, and why he urges other investors to adopt them as a pre-competitive practice. This episode of The BioCentury Show is brought to you by Tigermed.
View full story: https://www.biocentury.com/article/661356
#PatientEngagement #BiotechInvesting #ImpactInvesting #VentureCapital #MarketAccess
0:00 Introduction
2:00 Creating Gilde's Impact Council
7:32 Advisors' Impact on Investing
16:42 Gilde's Approach to Patient Engagement
23:50 Where Patient Input Fits in Decision-making
29:17 Why Other Investors Should EngageChapitres (6)
Ep. 122 - Tigermed's Britney Winterberger's take on running trials in the U.S. and China
Tigermed, the largest clinical CRO in China, has expanded into more than 50 countries and is growing its North American operations, offering full-service support from preclinical through Phase IV. On this …
Notes de l’épisode
Tigermed, the largest clinical CRO in China, has expanded into more than 50 countries and is growing its North American operations, offering full-service support from preclinical through Phase IV. On this sponsored edition of The BioCentury Show, Britney Winterberger, Tigermed’s VP and head of North America clinical operations, tells BioCentury Executive Editor Jeff Cranmer how the CRO helps U.S. sponsors run trials in China and Chinese sponsors run trials in the U.S. — and why combining both in a single protocol can de-risk FDA acceptance while capturing China’s enrollment speed. Winterberger also discusses investigator-initiated trials in China, China’s new IIT regulations, and trial trends spanning bispecifics, ADCs, cell and gene therapies, and radiopharmaceuticals.
This episode of The BioCentury Show is brought to you by Tigermed.
View full story: https://www.biocentury.com/article/661260
#GlobalClinicalTrials #IITs #Oncology #ADCs #CRO
0:00 Introduction
1:17 Tigermed's Global Capabilities
2:59 Running Trials in China
7:05 Chinese Sponsors in the U.S.
16:42 IITs
22:28 Trends in Trial DesignChapitres
Chargement des chapitres…
Ep. 121 - Arrowhead’s Chris Anzalone on the future of RNAi
Arrowhead Pharmaceuticals can now deliver siRNA to seven cell types, and new data showing subcutaneous delivery to the brain could push RNAi therapies well beyond the liver. On this edition of The BioCentury …
Notes de l’épisode
Arrowhead Pharmaceuticals can now deliver siRNA to seven cell types, and new data showing subcutaneous delivery to the brain could push RNAi therapies well beyond the liver. On this edition of The BioCentury Show, Arrowhead Chairman, President, and CEO Chris Anzalone joins BioCentury’s Stephen Hansen to discuss where siRNA has the edge over ASOs, what the Phase III miss for Novartis’ pelacarsen means for olpasiran, the Lp(a) therapy Arrowhead partnered with Amgen, and the growth outlook for plozasiran in severe hypertriglyceridemia. Anzalone also describes Arrowhead’s obesity programs targeting INHBE and ALK7, and a dimer molecule that silences two genes at once.
View full story: https://www.biocentury.com/article/661194
#RNAi #siRNA #DrugDelivery #DrugDevelopment #Biotech
0:00 Introduction
1:09 Arrowhead's siRNA Platform
9:05 Solving for Extra-Hepatic Delivery
23:43 Redemplo's Future Growth
27:00 Obesity and Bispecific siRNAChapitres
Chargement des chapitres…
Ep. 120 - Canaan’s Julie Grant on building biotechs in white spaces
Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant, co-founder and first CEO of Day One …
Notes de l’épisode
Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant, co-founder and first CEO of Day One, which Servier acquired for $2.5 billion this year. In an interview with BioCentury's Lindsay Martin, Grant discussed white spaces in women's health such as migraine and anemia, and why mid-tier acquirers like Jazz, Ipsen and Servier make smaller markets viable. She also explained why the last private round can understate value by 10-20X, how Canaan builds management teams around a key individual who sets the tone and why biotech needs scientific heroes as AI captures most venture dollars.
View full story: https://www.biocentury.com/article/660963
#VentureCapital #Biotech #WomensHealth #DrugDevelopment #BiotechMA
0:00 Introduction
1:19 Canaan's Strategy
11:34 Team Building
21:57 White Space
28:00 New Biotech Buyers
34:15 Biotech FoundersChapitres
Chargement des chapitres…
Ep. 119 - Blackstone's Galakatos on funding biotech's hardest mile
On this edition of The BioCentury Show, Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to Blackstone's new $6.3 billion …
Notes de l’épisode
On this edition of The BioCentury Show, Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to Blackstone's new $6.3 billion fund, and the goal of game-changing bets.
Galakatos discusses Blackstone's thesis for addressing the late-stage financing gap, as Phase III programs costing more than $1 billion drive demand for large, product-based capital. He also addresses structured capital as an alternative to acquisition, noting deals such as Blackstone's with Alnylam and Apogee can reduce dilution and extend runway.
View full story: https://www.biocentury.com/article/660824
#Biotech #PrivateEquity #DrugDevelopment #LifeSciences #ClinicalTrials
0:00 Introduction
1:22 New Fund & Founding
10:30 Alnylam Deal
17:14 Working with Big Caps
25:54 Biotech Risk
29:13 ChinaChapitres
Chargement des chapitres…
Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets
On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to discuss genetics as a scalable …
Notes de l’épisode
On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to discuss genetics as a scalable drug discovery platform and the practical use of AI in genomics.
View full story: https://www.biocentury.com/article/660697
#Genomics #DrugDiscovery #AI #GeneticMedicines #ClinicalTrials
0:00 - Introduction
1:14 - Regeneron Genetics Center
10:29 - Acting on Genetic Signals
16:57 - Getting to Drug Development
21:51 - Best AI Use CasesChapitres
Chargement des chapitres…
Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient
The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could eventually extend across all genetically …
Notes de l’épisode
The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could eventually extend across all genetically defined diseases. The initiative seeks to bring form to FDA’s Plausible Mechanism Framework by standardizing how evidence and methods can be reused across therapies and patients.
In conversation with Biopharma Analyst Dr. Tierney Baum on The BioCentury Show, C-Path CEO and CSO Klaus Romero discusses how the principal bottleneck is no longer the ability to design therapies for individual patients but rather the absence of a standardized regulatory and development system that can translate one success into many. C-Path plans to bring companies, academics, patient groups, and regulators together to share data and address recurring development bottlenecks.
View full story: https://www.biocentury.com/article/660583
#GeneticMedicines #RareDisease #DrugDevelopment #RegulatoryScience #ClinicalTrials
00:00 - Introduction
01:44 - Current Framework
07:01 - Process-based Regulation
13:57 - Overcoming Bottlenecks
20:28 - Use of AI
25:25 - Beyond Rare DiseasesChapitres
Chargement des chapitres…
Ep. 116 - Ovid's Jeremy Levin on biotech in the balance
Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to …
Notes de l’épisode
Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an interview with BioCentury Washington Editor Steve Usdin, Levin discussed why he believes industry leaders should speak out, and why many remain silent, about critical issues. He described concerns about the strength of the pillars that support the U.S. biotech industry, and why he is optimistic about the future of biotech.
View full story: https://www.biocentury.com/article/660408
#Biotech #DrugPricing #BiopharmaPolicy #ChinaBiotech #Innovation
00:00 - Introduction
03:24 - Biotech Under Threat
10:38 - CEO Compensation
15:39 - Competing with China
22:08 - U.S. Policy Prescriptions
30:00 - Looking AheadChapitres
Chargement des chapitres…
Ep. 115 - Initiate's Owens on what it takes to be AI-native
As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intractable problems, not just streamline …
Notes de l’épisode
As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intractable problems, not just streamline workflows. On The BioCentury Show, Owens breaks down how she evaluates founders, when Initiate chooses to fund versus co-found a company, and why she believes proprietary data now matters more than any proprietary model.
Owens also discusses gaps in evidence generation for diagnostics, and closes with a look at MASH, arguing that better non-invasive fibrosis staging will become increasingly critical as more GLP-1 combination therapies reach patients.
View full story: https://www.biocentury.com/article/660203
#AI #VentureCapital #Diagnostics #HealthTech #DrugDevelopment
00:00 - Introduction
01:15 - Initiate Ventures' Thesis
07:04 - What Makes Founders Fundable
17:36 - Defining AI Native Healthcare
23:20 - Diagnostics & Evidence Generation
36:44 - Non-Invasive Fibrosis TestingChapitres
Chargement des chapitres…
Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model
Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an evolution toward an original goal …
Notes de l’épisode
Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an evolution toward an original goal, which could soon be realized with the approval and launch of brepocitinib this year.
In conversation with Lindsay Martin on The BioCentury Show, Gline discussed how Roivant’s initial hub-and-spoke approach has provided the foundation needed for the company to develop and commercialize its portfolio now, including lead program JAK-1/TYK2 inhibitor brepocitinib. Gline also discussed how he views AI at Roivant and more broadly in biopharma R&D, the science behind Roivant’s next most advanced program, Phase III anti-FcRN mAb imeroprubart and the lessons he’s taking from a “graduating class” of biotechs that have launched programs, like Alnylam and Argenx S.E.
View full story: https://www.biocentury.com/article/660059
#DrugDevelopment #BiotechInnovation #Commercialization #ArtificialIntelligence #BiopharmaStrategy
00:00 - Introduction
00:42 - Roivant’s Evolution
09:19 - AI in R&D
17:48 - Lead Asset Brepocitinib
28:23 - Anti-FcRN mAb Imeroprubart
32:23 - China
37:55 - What’s Next for RoivantChapitres
Chargement des chapitres…
Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking
Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the …
Notes de l’épisode
Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the leadership of Frank Jiang, EVP and chief strategy officer, Hengrui is engaging in a range of dealmaking and using its partnerships as stepping stones toward its goal of becoming one of the top biopharma companies in the world.
In conversation with Executive Editor Jeff Cranmer on The BioCentury Show, Jiang describes the evolution of China’s biotech ecosystem — and Hengrui's — toward first-order innovation and the changing nature of deals in China, from straightforward licensing deals with “safe money” to NewCo deals and “co-co” partnerships.
View full story: https://www.biocentury.com/article/659912
#ChinaBiotech #BiopharmaInnovation #DrugDevelopment #StrategicPartnerships #GlobalBiotech
00:00 - Introduction
01:32 - Evolution of China Biotech
08:43 - China Deals
17:23 - Hengrui’s Evolution
24:43 - Shareholder Base
26:42 - DealsChapitres
Chargement des chapitres…
Ep. 112 - Chris Arendt on rebuilding Takeda for AI
Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds …
Notes de l’épisode
Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in Seattle, Arendt sat down with Editor in Chief Simone Fishburn to discuss how Takeda is integrating AI across R&D, in and beyond the science, while still executing on the active programs in drug development.
View full story: https://www.biocentury.com/article/659807
#ArtificialIntelligence #PharmaInnovation #DrugDevelopment #DigitalTransformation #ResearchAndDevelopment
00:00 - Introduction
02:07 - Revamping Takeda for AI
19:03 - Teams & Talent
26:43 - Alliances
32:50 - Q&AChapitres
Chargement des chapitres…
Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner
ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity …
Notes de l’épisode
ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The BioCentury Show, Genge discusses progress in pathway prioritization, progression-rate prediction, and endpoint standardization with BioCentury's Selina Koch.
On the biology side, Genge expects the field to converge on a small number of high-priority pathways. SOD1 is the first validated example, and AL-S Pharma is now testing whether misfolded SOD1 marks a treatable subset of sporadic ALS. On biomarkers, she's optimistic a TDP-43 marker could arrive within two years.
View full story: https://www.biocentury.com/article/659713
#ALS #DrugDevelopment #ClinicalTrials #Biomarkers #ALSResearch
00:00 - Introduction
02:03 - ALS Mechanistic Diversity
06:13 - Trial Design Challenges
16:52 - Biomarker Toolkit Update
24:20 - ALS Pharma & SOD1Chapitres
Chargement des chapitres…
Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China
Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of …
Notes de l’épisode
Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of knowing that millions of patients have benefited from the company’s medicines. He has led PDUFA reauthorization negotiations for industry, chaired BIO, and advocated for the interests of mid-sized biotechs.
As Pops prepares to retire as CEO (he will remain chairman), he spoke with BioCentury Washington Editor Steve Usdin about the ways policy and economics shape the development of medicines. Pops discussed the impact of the Trump administration’s most favored nation (MFN) drug pricing policy and the Inflation Reduction Act (IRA), concerns about FDA’s loss of talent, and competition and collaboration with China’s life sciences sector.
View full story: https://www.biocentury.com/article/659601
#DrugPricing #BiotechLeadership #FDAPolicy #LifeSciencesPolicy #DrugDevelopment
00:00 - Introduction
01:40 - Alkermes’ Evolution
05:12 - PBMs, Pricing & Access
10:54 - IRA
18:14 - MFN
24:36 - PDUFA Negotiations
28:05 - FDA Staffing
31:40 - China & U.S. PolicyChapitres
Chargement des chapitres…
Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.”In a wide-ranging interview on …
Notes de l’épisode
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.”
In a wide-ranging interview on The BioCentury Show with BioCentury Washington Editor Steve Usdin, Knudsen discussed the Parker Institute’s focus on accelerating the path from scientific breakthrough to medical impact.
As it approaches its tenth anniversary, the institute has deployed about $400 million, catalyzing roughly $4 billion in follow-on investment across 17 companies.
View full story: https://www.biocentury.com/article/659476
#CancerImmunotherapy #TranslationalScience #DrugDevelopment #Biopharma #CancerResearch
00:00 - Introduction
01:34 - Optimizing Translation
07:42 - Training the Immune System
16:33 - China’s Opportunity
20:50 - Need for a Cancer Strategy
24:40 - Enhancing Cancer Survivorship
27:55 - Scientific Foundation Under ThreatChapitres
Chargement des chapitres…
Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy
A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal …
Notes de l’épisode
A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal biology, according to Syncona CEO Chris Hollowood.
Hollowood spoke on The BioCentury Show with Editor in Chief Simone Fishburn about how discovery is evolving, why causal biology has been stuck in a loop of circularity, and where the U.K. investor is headed. He also discussed the firm’s approach to gene therapy investments, how it is surmounting the field’s challenges and Syncona’s pivot last year, with a portfolio shift from 25% to over 85% clinical-stage companies.
View full story: https://www.biocentury.com/article/659341
#CausalBiology #GeneTherapy #BiotechInvesting #DrugDiscovery #ClinicalStage
00:00 - Introduction
01:06 - Rational Target Discovery
16:48 - Gene Therapy
23:15 - Syncona’s StrategyChapitres
Chargement des chapitres…
Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing
The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But …
Notes de l’épisode
The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-founder and managing director Sander Slootweg says there’s still more that can be done to fund future European innovations and improve Europe’s competitiveness globally.
“We’ve observed in Europe that although we see great science, and we’ve been able to build great companies, in terms of the absolute magnitude of the ecosystem, we’re still lagging behind the U.S., and also China is coming up quickly,” Slootweg said in conversation with BioCentury's Stephen Hansen.View full story: https://www.biocentury.com/article/659150
#EuropeanBiotech #VentureCapital #BiotechFunding #Bioeconomy #GlobalInnovation
00:00 - Introduction
01:34 - Forbion’s growth
05:35 - Deal flow in Europe
10:20 - Green Investing
14:24 - Sourcing Asia Deals
22:20 - Unlocking the EU’s Capital
27:54 - Speeding Up Trials
30:13 - Building a Thriving EU Market
34:38 - Central & Eastern EuropeChapitres
Chargement des chapitres…
Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform
The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now …
Notes de l’épisode
The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now putting serious efforts into solving.
Mahony, one of the major influential figures in U.K. biotech, is a senior partner in growth investments at Novo Holdings, and was until December chair of the U.K.’s BioIndustry Association (BIA). In conversation with BioCentury Editor in Chief Simone Fishburn on The BioCentury Show, Mahony discussed the future of U.K. and European biotech, and the intersection of reforms related to financing and clinical trials, as well as the need for a rethink on drug pricing.
View full story: https://www.biocentury.com/article/658997
#UKBiotech #BiotechInnovation #DrugPricing #HealthcareReform #LifeSciencesPolicy
00:00 - Introduction
01:40 - U.K. Clinical Trial Reform
04:23 - Funding U.K. Biotech
10:40 - Propagating Innovation
15:08 - Measuring Progress
18:22 - Drug Pricing
22:40 - Scaling Europe’s Biotechs
25:16 - AI in BiotechChapitres
Chargement des chapitres…
Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers
As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan …
Notes de l’épisode
As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI is showing measurable value now, how public techbio companies are being pushed toward proof points, and what comes next — from out-of-domain prediction to stronger data foundations and precompetitive collaboration.
View full story: https://www.biocentury.com/article/658829
#ArtificialIntelligence #DrugDevelopment #AgenticAI #ClinicalProof #BiopharmaInnovation
00:00 - Introduction
01:41 - AI Hype to Proof
04:52 - Where AI Adds Value
13:30 - AI for Clinical Trials
17:01 - Agentic AI in R&D
25:34 - Out-of-Domain Prediction
28:24 - Future of Techbio
31:13 - Precompetitive Consortia
35:24 - CEO Leadership and CatalystsChapitres
Chargement des chapitres…
Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity
There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI tools across biopharma has been much …
Notes de l’épisode
There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI tools across biopharma has been much slower relative to the broader healthcare environment, SoftBank’s Jacqueline Fok said on The BioCentury Show.
In conversation with BioCentury's Stephen Hansen, Fok, who is investment director, Life Sciences & Health Tech at SoftBank Investment Advisers, also detailed SoftBank’s investment strategy in life sciences and the opportunity the U.K. has to stand out as a globally competitive player, with SoftBank’s obesity portfolio company Metsera as a recent example of success.
View full story: https://www.biocentury.com/article/658661
#ArtificialIntelligence #DrugDevelopment #BiotechInvestment #UKBiotech #ObesityDrugDevelopment
00:00 - Introduction
01:30 - SoftBank Strategy
08:40 - Metsera
14:48 - U.K. Biotech
21:38 - AI
28:20 - Women in Leadership
32:03 - Fok’s CatalystsChapitres
Chargement des chapitres…
Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA Are Slowing Drug Development
Caution: This episode of The BioCentury Show contains strong language.In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at …
Notes de l’épisode
Caution: This episode of The BioCentury Show contains strong language.
In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at FDA are slowing drug development and pushing companies to launch early-stage trials outside the U.S.
In conversation with BioCentury Washington Editor Steve Usdin, Kolchinsky also discusses U.S. policy headwinds, including most-favored-nation (MFN) pricing proposals and the Inflation Reduction Act’s “pill penalty,” and why he’s concerned that the biopharma sector is too “genteel” in its advocacy. Kolchinsky explains his decision to speak publicly about regulatory and political issues, including immigration, and reflected on China’s expanding role in the global life sciences innovation ecosystem.
View full story: https://www.biocentury.com/article/658433
#BiotechPolicy #FDALeadership #DrugPricingPolicy #LifeSciencesInnovation #CapitalMarkets
00:00 - Introduction
00:37 - Impact of FDA Policy Changes
06:17 - MFN & Drug Pricing in Europe
20:16 - The Importance of Speaking Up
34:26 - China & InnovationChapitres
Chargement des chapitres…
Ep. 102 - Psychiatry R&D: Steve Paul on Serendipity, Engineering and What Drives Real Breakthroughs
With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery, selectivity and tolerability fixes are turning …
Notes de l’épisode
With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery, selectivity and tolerability fixes are turning long-standing hypotheses into usable medicines, says veteran CNS drug developer Steven Paul. Few drug developers have had a closer view of the field’s false starts — and occasional breakthroughs — than Paul, who has moved from NIH to pharma R&D leadership and now to company building at Karuna, acquired by BMS for $14 billion, and Seaport.
In conversation with The BioCentury Show's Selina Koch, Paul explains why serendipity still plays a disproportionate role in psychiatric drug development and how critical it is for teams to engineer and execute their way from an unexpected signal to a usable medicine. He also discusses psychedelics, brain shuttles, Karuna’s muscarinic approach in schizophrenia, and the delivery and trial-design choices Seaport is using to revisit neuroactive steroid biology in depression.
View full story: https://www.biocentury.com/article/658314
#PsychiatryTherapeutics #CNSDrugDevelopment #BiotechEngineering #Psychedelics #NeuroScience
00:00 - Introduction
01:32 - Psychiatric Drug Discovery
06:56 - The Karuna Story
22:09 - What’s New in Depression
32:06 - Gene Therapies, Brain Shuttles
33:53 - PsychedelicsChapitres
Chargement des chapitres…
Ep. 101 - Why Science Stalls: Astellas CEO Naoki Okamura on Translation, Talent and Platforms
Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s translation: a shortage of people, processes and platforms that …
Notes de l’épisode
Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s translation: a shortage of people, processes and platforms that can move ideas across the boundaries of biology, manufacturing, regulation and commercialization. That theme threaded through his conversation on The BioCentury Show with Executive Editor Selina Koch, surfacing most clearly in his diagnosis of what Japan’s biotech ecosystem lacks — and in his rationale for why Astellas is doubling down on cell and gene therapy as other multinational pharmas pull back. The discussion also touches on Astellas’ journey in commercializing a women’s health product, the company’s China strategy, and its plans for life after Xtandi’s patent cliff.
View full story: https://www.biocentury.com/article/658141
#BiotechTranslation #CellAndGeneTherapy #JapanBiotech #PharmaStrategy #DrugDevelopment
00:00 - Introduction
00:39 - Cell & Gene Therapy
07:22 - Women’s Health
13:00 - Japan’s Biotech Ecosystem
19:00 - Astellas’ China Strategy
22:45 - Astellas’ Near-Term StrategyChapitres
Chargement des chapitres…
Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next
Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capital, alongside PE firms’ increasing …
Notes de l’épisode
Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capital, alongside PE firms’ increasing ability to conduct the technical diligence required for investments once considered too risky for their models.
In conversation with The BioCentury Show's Stephen Hansen, Bain Capital’s Adam Koppel discussed the evolution of private equity's interest in biotech, Bain’s prioritization scheme for scaled investments and his outlook for the capital markets in the year ahead.
View full story: https://www.biocentury.com/article/657997
#PrivateEquity #BiotechDeals #LifeSciencesInvesting #GrowthEquity #BiopharmaMarkets
00:00 - Introduction
01:57 - PE's Evolution in Biotech
06:58 - Bain's Priorities
11:24 - Structuring Deals
18:23 - Capital Market Conditions
24:03 - Environment for Private Companies
27:08 - IPO OutlookChapitres
Chargement des chapitres…
Ep. 99 – Stelios Papadopoulos on Biotech’s Long View: Pricing Pressure, China & Big Pharma
In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, but the level of anxiety in biotech doesn’t reflect the …
Notes de l’épisode
In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, but the level of anxiety in biotech doesn’t reflect the “extraordinary science, the likes of which we’ve never seen — and it’s getting better,” said Papadopoulos on The BioCentury Show.
Papadopoulos is one of the long-term leading voices of biopharma, recognized for his influence in shaping the industry. Former chair of Biogen and current chair of Exelixis, with roles on several boards, and a background of nearly two decades as an investment banker, he brings a long view to how the industry has grown and the forces driving where it is headed. Tune in to hear his take on the financing environment for biotechs, company building, pricing pressure, innovation from China, and the future of big pharmas, in conversation with Editor in Chief Simone Fishburn.
View full story: https://www.biocentury.com/article/657910
#BiotechOutlook #DrugPricing #ChinaBiotech #BigPharma #BiopharmaStrategy
00:00 - Introduction
02:00 - Financing Environment
10:18 - Company Building
20:47 - Women in Biotech
25:38 - China, Korea & Europe
30:00 - Is Biotech Too Insular?Chapitres
Chargement des chapitres…
Ep. 98 - Inside Precision Oncology’s Next Chapter with Fore’s Bill Hinshaw
When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Biotherapeutics — he sees a precision oncology field transformed …
Notes de l’épisode
When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Biotherapeutics — he sees a precision oncology field transformed by technological ambition, yet still grappling with many of the structural challenges that defined its beginnings, now compounded by the difficulty of positioning therapies within an ever more complex treatment landscape.
Gleevec proved the power of targeting a genomic driver, but the healthcare system around it was far from ready. “We weren’t able to fulfill the promise as fast as we wanted to until that scaling happened,” Hinshaw told The BioCentury Show — a reminder that even today, precision medicines succeed or fail based not only on their biology but on the infrastructure that enables patients to access them.
Hinshaw sat down with Executive Editor Selina Koch on The BioCentury Show to discuss what’s changed in precision oncology, what’s stayed the same, and how he’s applying those lessons to steer Fore’s BRAF-focused program.
View full story: https://www.biocentury.com/article/657768
#PrecisionOncology #BRAFAlterations #NGSTesting #MasterProtocol #TargetedTherapies
00:00 – Introduction
00:47 – Precision Medicine’s Evolution
09:22 – Zeroing in on Subtypes
17:59 – Fore’s BRAF Inhibitor
26:38 – Fore’s Development Approach
32:01 – Moving from Pharma to BiotechChapitres
Chargement des chapitres…
Popular Episode - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future
This is a previously recorded episode of The BioCentury Show from September 5, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior …
Notes de l’épisode
This is a previously recorded episode of The BioCentury Show from September 5, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.
If you could redesign FDA from the ground up, what would it look like? That’s the fundamental question underlying the 2025 BioCentury Back to School essay, authored by BioCentury Washington Editor Steve Usdin, who has been a leading voice on regulation and policy for over two decades. The topic is especially meaningful in this era of FDA turmoil, when regulatory risk has piled on top of the market pullback, making biotech appear an unusually hazardous domain for investors. But while the current landscape has underscored the need, FDA reform has been on the table long before this administration came into power. On this edition of The BioCentury Show, Usdin and Editor in Chief Simone Fishburn discuss the key arguments, and some specific concepts, within Back To School, which reimagines the U.S. drugs regulator.
View full story: https://www.biocentury.com/article/656928
#FDA #DrugRegulation #Biopharma #LifeSciences #Biotech #PublicTrust
00:00 - Introduction
02:39 - Restructuring FDA
18:08 - A Learning Regulatory Agency
27:54 - Global View
31:09 - Talent
32:59 - User FeesChapitres
Chargement des chapitres…
Ep. 97 – From NIH to Industry: Zerhouni Warns Policy & Rhetoric Threaten U.S. Science
Elias Zerhouni personifies the American dream. He arrived in the U.S. from Algeria as a young man with a couple of hundred dollars in his pocket. Talent, ambition and hard work propelled him into a successful …
Notes de l’épisode
Elias Zerhouni personifies the American dream. He arrived in the U.S. from Algeria as a young man with a couple of hundred dollars in his pocket. Talent, ambition and hard work propelled him into a successful academic career. In 2002, he was nominated and confirmed as NIH director, and later he served in senior positions in the biopharma industry. That trajectory “would be almost impossible” today, he told BioCentury Washington Editor Steve Usdin on The BioCentury Show.
Anti-immigration policies, underfunding of basic research, and attacks on philanthropy have made the U.S. an unattractive destination for anyone hoping to follow his path, Zerhouni said.
Zerhouni also discussed reasons for optimism about life sciences in the U.S., the difficulty of fixing drug pricing, and his time at Sanofi.
View full story: https://www.biocentury.com/article/657591
#NIH #BiomedicalInnovation #ImmigrationPolicy #Biopharma #LifeSciences #HealthcareReform #MedicalResearch
01:09 - The American Dream & Science
05:51 - Zerhouni at NIH
09:40 - Loss of Trust
16:53 - Vaccine Policy
20:12 - Zerhouni in Industry
23:20 - Drug PricingChapitres
Chargement des chapitres…
Ep. 96 – From Pharma Partnering to Biotech CEO: Sophie Kornowski on Boston Pharma’s Playbook
It took Sophie Kornowski under four years as CEO of Boston Pharma to bring it from a pipeline full of in-licensed assets to an acquisition by GSK for about $2 billion in total deal value for a single MASH …
Notes de l’épisode
It took Sophie Kornowski under four years as CEO of Boston Pharma to bring it from a pipeline full of in-licensed assets to an acquisition by GSK for about $2 billion in total deal value for a single MASH program. Though her first gig as a biotech CEO, Kornowski’s success was built on her years of experience as head of partnering at Roche. She discussed that pivot and the value of rolling your sleeves up on the latest episode of The BioCentury Show.
View full story: https://www.biocentury.com/article/657446
#BiotechLeadership #DrugDevelopment #PharmaDeals #BiotechCEO #StartupSuccess #LifeSciences #MetabolicDisease #PharmaInnovation
00:00 - Introduction
01:15 - Becoming a Biotech CEO
11:40 - MASH
18:15 - First v. Best in Class
24:10 - GSK DealChapitres
Chargement des chapitres…
Voici les 40 derniers épisodes sur 76. Les épisodes plus anciens se trouvent dans le flux du podcast.
Recommandé par The BioCentury Show
Podcasts similaires
Plus de podcasts : Affaires
C’est votre podcast ?
Confirmez-le avec une entrée dans votre flux : vous recevez ici un code, vous l’ajoutez comme podcast:txt dans le canal de votre flux, et nous le vérifions. Votre podcast apparaît ensuite comme « vérifié » sur SoundNode.